Retina Synthesis

Carl Danzig discusses two-year results from PRISM, the Phase 1/2 trial of 4D-150, a single in-office intravitreal gene therapy that turns the retina into a biofactory producing aflibercept and blocking VEGF-C. In recently diagnosed patients, vision and retinal thickness were maintained, 66% needed no supplemental injections over two years, and the group averaged just 1.6 supplemental injections. D...

Anton Kolomeyer walks through Vestrum Health data on intravitreal injection use from 2023 to 2025, presented at ASRS 2026. Bevacizumab climbed to about 30 percent of injections in 2025, passing aflibercept 2 milligrams, which fell from nearly 46 percent, as the loss of Good Days copay assistance left Medicare Advantage patients unable to afford branded drugs. He covers the growth of faricimab, afl...

Help Shape What’s Next on Retina Synthesis Tell us what you enjoy and what you’d like to hear more of. Our listener survey is anonymous and takes under 3 minutes. Your feedback will help guide future episodes. Take the survey: https://docs.google.com/forms/d/e/1FAIpQLSfPvwGmK_zEzF7x5f7bBM78nCsYLyS6Ga3jrJMAHg2FmvtLng/viewform Thank you for being part of the Retina Synthesis community! Dr. Raj Matur...

Dr. Ashkan Abbey, Director of Clinical Research at Texas Retina Associates, returns to discuss vonaprument (ANX007), a C1q inhibitor that blocks complement upstream of C3 and C5. In Phase 2 ARCHER, monthly treatment cut the risk of ≥15-letter vision loss by about 73% and preserved photoreceptors on OCT, while lesion growth on autofluorescence did not change. He explains the Phase 3 ARCHER II desig...

Can a drop replace the needle in diabetic macular edema? Dr. Veeral Sheth returns to Retina Synthesis to walk through DIAMOND-1 and DIAMOND-2, Oculis's twin Phase 3 trials of OCS-01, a high-concentration (15 mg/mL) topical dexamethasone formulated to reach the posterior segment. Across 800+ patients with mild-to-moderate DME, the drop did what it was supposed to do anatomically — central thic...

We welcome back Dr. Roger Goldberg from Bay Area Retina Associates, in our latest episode to discuss the BARDENAS trial (NCT05151744) a global Phase 2 clinical study evaluating the efficacy and safety of vamikibart (RO7200220), an IL-6 inhibitor, combined with ranibizumab for treating diabetic macular edema (DME). 

In this episode, we discuss the surgical technique and complications associated with implantation of an encapsulated cell therapy for MacTel 2 with Dr. Lloyd Clark from North Carolina Retina Association.

In this episode, we discuss the results of the Phase 3 Lugano Trial from Eyepoint Pharmaceuticals with Dr. Carl Regillo of Wills Eye Hospital.

In this episode we discuss the use of  a subcutaneously administered tyrosine  kinase inhibitor migaldendranib (D-4517.2)  or MGB for the treatment of neovascular AMD and diabetic macular edema with Dr. Michael Singer from San Antonio

In this episode, we review the current status of gene therapy for inherited retinal degenerations with Dr. Ninel Gregori, Professor of Clinical Ophthalmology, Bascom Palmer Eye Institute

In this episode, we discuss the latest developments in faricimab therapy of polypoidal choroidal vasculopathy, with Dr. Gemmy Cheung, Head of the Medical Retina Division, at the Singapore National Eye Center.

In this episode, we review the work of the Research in Safety and Therapeutics (ReST)Committee of the American Society of Retinal Specialists (ASRS) with Dr. Andre Witkin, Chair of the ReST Committee, and Professor of Ophthalmology at Tufts University School of Medicine, New England Eye Center, and Ophthalmic Consultants of Boston.

In this episode, we discuss potential new treatments for geographic atrophy of age related macular degeneration with Dr. Jessica Randolph of Wagner Kapoor Institute in Richmond, Virginia.

In this episode, we discuss the use of handheld ERG in the evaluating eye with diabetic retinopathy. ERG is a powerful predictive tool in assessing diabetic retinopathy. Our guest is Dr. Raj Maturi of the Midwest Eye Institute and Adjunct Associate Professor of Ophthalmology, at the Indiana University School of Medicine.

In this episode, we discuss the long term results of faricimab therapy of neovascular AMD with Dr. Carl Danzig of Fort Lauderdale, Florida and Affiliate Assistant Professor at the Charles Schmidt School of Medicine at Florida Atlantic University.

In this episode, we discuss 5 year results of the GALE study which demonstrated that earlier treatment with pegcetacoplan of geographic atrophy preserves more retinal tissue with Dr. Dilsher Dhoot, California Retina Consultants, Adjunct Clinical Assistant Professor Ophthalmology, Roski Eye Institute, Keck School of Medicine of USC.

In this episode, we discuss the importance of early recognition of PCV, diagnostic techniques, and therapeutic approaches with Professor Jay Chhablani of the University of Pittsburgh.

In this episode, we review the evidence regarding the effectiveness of AREDS vitamin supplementation in affecting the growth of geographic atrophy in age related macular degeneration.

In this episode, we discuss the promising results of intravitreal gene therapy for neovascular AMD with 4D-150 with Dr. Arshad Khanani of Sierra Eye Associates and Clinical Professor of Ophthalmology at the University of Nevada Medical School, Reno.

In this episode, we discuss the latest developments in the use of artificial intelligence in home OCT for management of neovascular AMD with Professor Anat Loewenstein of Tel Aviv Medical Center and President, Israeli Ophthalmology Society.

We discuss long term results of faricimab treatment of DME, with the first author of the Ophthalmology article on the results of Rhone-X trial, Dr. Veeral Sheth, Director of Clinical Research at University Retina in Chicago.

In our latest episode we discuss the results of a novel approach to the treatment of geographic atrophy using Xelafaslatide a Fas inhibitor with Dr. David Zacks, Professor of Ophthalmology at the Kellogg Eye Center at the University of Michigan.

In our latest episode, we discuss the use of inhibitors of IL-6 in the treatment of retinal disease with Dr. Steven M. Yeh, Stanley M. Truhlsen, Jr. , Chair of Ophthalmology a the University of Nebraska.

In this episode, we discuss the use of aflibercept 8mg for the management of retinal vein occlusion and the results of the QUASAR study with Dr. Sunir Garg, Co Director of Retina Research at the Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University.

In this episode we discuss the results of a phase 2 trial using subcutaneous elamipretide for the treatment of geographic atrophy with Dr. Mark Barakat.